Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development 12 February 2024
- Hikma – A legacy of quality for a better future Insight, Corporate 24 June 2024 Hikma – A legacy of quality for a better future
- Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D Press Release, Corporate 17 June 2024 Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D
- Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting Press Release, Corporate 06 June 2024 Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting
- Hikma opens new UK office to support NHS supply, strengthening European presence Press Release, Corporate 03 June 2024 Hikma opens new UK office to support NHS supply, strengthening European presence
Related content